First Heartland Consultants, Inc. Bio Line Rx Ltd. Transaction History

First Heartland Consultants, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 11, 2022	SELL	$1.98 - $3.06 $19,800 - $30,600	-10,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.38 - $4.0 $23,800 - $40,000	10,000 New	10,000 $28,000

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of First Heartland Consultants, Inc., based on Form 13F filings with the SEC.

Stay updated on First Heartland Consultants, Inc. with notifications on news.